In this issue:
ATLAS: MRD-guided maintenance intensification
Real-world outcomes of patients undergoing third-line therapy
Patients', clinicians' and research's priorities on important outcomes
Upfront CAR T-cell therapy promising for transplant-ineligible disease
Strong joint prognostic value for MRD + PET-CT response assessments
High real-world early mortality after bispecifics
2025 IMS-IMWG consensus genomic staging
Belamaf-based quadruplet induces deep and durable responses in RRMM
Could ruxolitinib treat CAR T-cell–associated intractable diarrhoea?
PSMD1 identified as a novel therapeutic target
Please login below to download this issue (PDF)